Drug-Drug and Drug-Disease Interactions in Clinical Study Report
ICH E3 section 11.4.5 calls for efficacy discussion of drug-drug and drug-disease interactions when they are relevant to the study findings. Do not turn the subsection into a general pharmacology interaction catalogue; keep it tied to interactions evaluated or observed in the reported clinical study.
ReviewedEvidence1 sourceSectionWriting & Style
Quick answer
This CSR subsection explains whether concomitant drugs or relevant disease states appear to modify the treatment response and how that evidence was assessed.
Key details
Core IssueICH E3 section 11.4.5 calls for efficacy discussion of drug-drug and drug-disease interactions when they are relevant to the study findings.
Registerscholarly, professional, or research/report writing
Important caveats
Scope Boundary
Do not turn the subsection into a general pharmacology interaction catalogue; keep it tied to interactions evaluated or observed in the reported clinical study.
Further guidance
Content
Report the interaction analyses actually supported by the study design and data, including relevant subgroups or concomitant-treatment context where appropriate.
Purpose
This CSR subsection explains whether concomitant drugs or relevant disease states appear to modify the treatment response and how that evidence was assessed.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
ICH E3 section 11.4.4 addresses relationships among dose, measured drug concentration, and clinical response when those data are relevant to interpreting efficacy. This results-level relationship analysis is distinct from documenting how doses were selected or how concentrations were measured during study conduct.
ICH E3 section 12.3.3 calls for analysis and discussion across deaths, other serious adverse events, and other significant adverse events after the relevant case listings and narratives. This is an interpretive synthesis, not a duplicate death/serious-event listing or a replacement for individual patient narratives.
ICH E3 Section 13 calls for a concise discussion of efficacy and safety results, the risk-benefit relationship, unexpected findings, clinical relevance, unresolved issues, and implications for future studies without merely repeating results or introducing new ones. This section interprets results already presented; it should not simply duplicate result tables and should not introduce new study results that were not reported elsewhere.
ICH E3 section 9.5.4 identifies drug concentration measurements as a distinct investigational-plan subsection when such measurements are part of the study. This methods subsection is distinct from patient-level laboratory-data listings and from later analyses relating dose or concentration to clinical response.
ICH E3 Section 9.5 calls for identification of the efficacy and safety variables assessed, the methods and timing of assessments, and the people or procedures responsible for measurements, often with a schedule or flow chart. This section defines variables and assessment methods; it is not the same artifact as the later efficacy or safety result tables.
ICH E3 states that estimated or derived values used in a table, figure, or data listing should be conspicuously identified and their derivation and underlying assumptions explained. This display rule is broader than the patient-level listing guide: it applies across tables, figures, and data listings wherever estimated or derived values appear.
ICH E3 describes the CSR as an integrated full report in which clinical and statistical descriptions, presentations, and analyses are brought together rather than simply joining separate reports. Integration does not require placing every technical detail in the main text; ICH E3 still uses appendices for supporting material and detailed documentation.
ICH E3 section 11.4.2.3 calls for interim analyses and data-monitoring activity relevant to the study results to be identified, including their timing, role, and implications for interpretation. Keep this CSR results/reporting scope separate from a general methods-only discussion of stopping rules or trial-governance policy.
